Open access
1,755
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States
Talha Munira Department of Haematology, Leeds Teaching Hospital NHS Trust, Leeds, UK
https://orcid.org/0000-0002-2901-0769View further author information
Victoria Genovezb Health Economics & Market Access, Amaris Consulting, Lisbon, PortugalView further author information
, Victor Genestierc Amaris Consulting, Toronto, CanadaView further author information
, Kellie Ryand Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USAView further author information
, Bengt Liljase Oncology Market Access & Pricing, AstraZeneca, Gaithersburg, MD, USACorrespondence[email protected]
View further author information
& View further author information
Priyanka Gaitondee Oncology Market Access & Pricing, AstraZeneca, Gaithersburg, MD, USAView further author information
Pages 579-589
|
Received 10 Aug 2022, Accepted 24 Mar 2023, Published online: 10 Apr 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.